BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

CureVac B.V

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.

Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development

Novavax

Novavax announced a wider Covid-19 vaccine manufacturing pact in India, while BioNTech announced $445 million in funding from Germany for its Covid effort; both stocks rose early Tuesday.
The post Covid Roundup: BioNTech Boosts Funding; Novavax Boosts Manufacturing appeared first on Investor's Business Daily.

Covid Roundup: BioNTech Boosts Funding; Novavax Boosts Manufacturing

BioNTech SE shares BNTX, +3.60% soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in funding from the German Federal Ministry of Education and Research to support the accelerated development of a COVID-19 vaccine in collaboration with partner Pfizer Inc.

BioNTech shares jump premarket on news of 375 million euros in German funding for COVID-19 vaccine

Mainz, Germany, Sept.  15, 2020  (GLOBE NEWSWIRE) --   MAINZ, GERMANY, September 15, 2020 —  BioNTech SE  (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it will receive a grant of up to 375 million Euro from an initiative by the German Federal Ministry of Education and Research (BMBF) to support the accelerated development of SARS-CoV-2 vaccines.  BioNTech will use the milestone-based BMBF funding to support its contribution to the Company’s mRNA vaccine program BNT162 that is being co-developed with its partners Pfizer Inc. and Fosun Pharma respectively.  The goal of the initiative is the expansion of vaccine development and manufacturing capabilities in Germany, as well as the expansion of the number of participants in late-stage clinical trials. The BNT162 vaccine program is one of three programs supported by the BMBF initiative, which will provide a total of up to 750 million Euro to its funding recipients.

BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162

Pfizer

The expansion shouldn't affect the initial data readout.

Pfizer and BioNTech Plan to Increase Size of Their Coronavirus Vaccine Clinical Trial

AstraZeneca

Moderna

The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the spoils.

What If More Than One Company Wins the Coronavirus Vaccine Race?

Inovio Pharmaceuticals

Johnson & Johnson

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S.

Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.

Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU

Reality Check For COVID Vaccines: Caution Moderna, BioNTech, Novavax

The duo is in contract negotiations with the European Commission.

Pfizer and BioNTech to Potentially Sell 300 Million Doses of Its Coronavirus Vaccine to EU

GlaxoSmithKline

Merck

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

BioNTech and Pfizer announced both positive early immunization data and a nearly complete supply deal for their Covid vaccine candidate, sparking shares of both BNTX stock and PFE stock.
The post Pfizer, BioNTech Ink Covid Vaccine Deal With EU, Post Positive Trial Data appeared first on Investor's Business Daily.

Pfizer, BioNTech Ink Covid Vaccine Deal With EU, Post Positive Trial Data

Shares of Pfizer Inc. (NYSE: PFE) and its coronavirus vaccine development partner BioNTech SE – ADR (NASDAQ: BNTX) are advancing Wednesday thanks to multiple catalysts.

Pfizer, BioNTech Rally On A Trio Of Catalysts

BioNTech BNTX, +2.15% and Pfizer Inc. PFE, -1.18% , which are developing a COVID-19 vaccine candidate, said in a news release on Wednesday that they plan to pursue regulatory review for BNT162b2 in October, depending on the success of the vaccine in late-stage clinical trials.

BioNTech, Pfizer expect clinical 'answer' on coronavirus vaccine in late October

Shares of several companies that are developing COVID-19 vaccines rallied on Wednesday morning before the market opened following a Stat News report published Tuesday that said AstraZeneca AZN, +2.10% [ AZN, -1.62% halted a Phase 3 clinical trial for its coronavirus vaccine candidate over safety concerns.

Moderna, BioNTech, Pfizer stocks rally after AstraZeneca COVID-19 vaccine trial is reportedly halted

NEW YORK and MAINZ, Germany, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. In a non-human primate preclinical study, immunization with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate, protected rhesus macaques against SARS-CoV-2 infection. The manuscript describing these preclinical data is available on the preprint server bioRxiv and is concurrently undergoing scientific peer-review for potential publication.

Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19

Shares of BioNTech SE BNTX, +2.15% rallied 5.0% in premarket trading Wednesday, and Pfizer Inc.

Pfizer, BioNTech conclude talks over supplying EU with SARS-CoV-2 vaccine candidate

NEW YORK and MAINZ, Germany, Sept.  09, 2020  (GLOBE NEWSWIRE) --  Pfizer  (NYSE: PFE) and  BioNTech SE  (Nasdaq: BNTX) today announced that they had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their investigational BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for further 100 million doses. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization. The companies will now enter into contract negotiations with the European Commission. 

Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others.

What Does a Perfect COVID-19 Vaccine Actually Mean?

Sanofi

Nine leading U.S. and European vaccine developers pledged to uphold the scientific standards that their experimental immunizations will be held against, amid a hurried global race to contain the pandemic.

Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine development

NEW YORK, Sept.  08, 2020  (GLOBE NEWSWIRE) -- The CEOs of  AstraZeneca  (LSE/STO/NYSE: AZN),  BioNTech SE  (NASDAQ: BNTX),  GlaxoSmithKline plc  (LSE/NYSE: GSK),  Johnson & Johnson  (NYSE: JNJ),  Merck  (NYSE: MRK), known as MSD outside the United States and Canada,  Moderna, Inc.  (Nasdaq: MRNA),  Novavax, Inc.  (Nasdaq: NVAX),  Pfizer Inc.  (NYSE: PFE), and  Sanofi  (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.

Biopharma Leaders Unite to Stand with Science

Buy BioNTech After The Ugly Dip Ends

A quick approval would be nice, but the drugmakers are sticking to their scientific principals.

Moderna, Pfizer, Johnson & Johnson, And Others To Make Pledge in Response to Coronavirus Vaccine Political Pressure

These businesses are backed by science, and they've already got orders lined up for their experimental vaccines.

News for BioNTech SE Stock (BNTX)